Everything below concerns Copper(II). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-01. Numbers and descriptions here follow the published literature rather than marketing material.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Sealed, desiccated, protected from light |
| Common analytical method | Reversed-phase HPLC with UV detection | Used for purity and identity screening |
| Mass spectrometric signal | About 402 m/z | Corresponds to the intact one-to-one complex |
| Visible absorption | Broad band near 525-630 nm | Arises from the copper coordination sphere |
| Preferred solvent | Water or dilute buffer | Strong chelators such as EDTA are avoided |
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
==== Pharmacokinetics of urea derivatives ==== Regorafenib and sorafenib reach mean peak plasma level in about 3 or 4 hours after a single oral dose. A high-fat meal decreases their absorption, while a low-fat meal may increase it, in comparison to taking the drugs in a fasting condition. In vitro protein binding is 99,5% for both drugs. The drugs are mainly metabolized in the liver by oxidative metabolism of CYP3A4, and glucuronidized by UGT1A9. Their half-life ranges from 20 to 48 hours. Most of the administered dose should be out of the system in around 14 days. The drugs are mostly excreted in faeces, around 70-80%, but also in urine.
In the European Union, the use of dimethyl fumarate in consumer product manufacturing has been forbidden since 1998, and in 2009 the importation of consumer products containing dimethyl fumarate was also forbidden. EU Commission Decision 2009/251 of 17 March 2009 required member states to ensure that consumer products containing dimethyl fumarate were not placed or made available on the market from 1 May 2009. This definitely outlawed any marketing of consumer products containing dimethyl fumarate in the European Union. The ban on dimethyl fumarate as laid down in Decision 2009/251 establishes a maximum dimethyl fumarate concentration in products of 0.1 ppm. The decision dictated that consumer products containing more than 0.1 ppm dimethyl fumarate should be withdrawn from the market and recalled from consumers.
==== Inflammatory and systemic autoimmune disorders ==== Conditions that may closely resemble polymyositis include dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy, systemic lupus erythematous, systemic sclerosis, and Sjögren syndrome. Overlapping skin features, such as facial redness/flushing in lupus, is an example of how these conditions can cause clinical confusion when diagnosing.
The liquid in such a vessel becomes increasingly enriched in oxygen (boiling point −183 °C, higher than that of nitrogen) as the nitrogen evaporates, and can cause violent oxidation of organic material.
Sources: en.wikipedia.org
After making the necessary adjustments to account for the n0 standard gas density, ion mobilities are often expressed as reduced mobilities. This number can also be described as standard temperature T0 = 273 K and standard pressure p0 = 1013 hPa. Both of these can be found in the table below. Ion concentrations are another term that may be used when referring to ion mobilities. Because of this, the decreased ion mobility is still temperature-dependent, although this adjustment does not consider any impacts other than the reduction in gas density.
== Further reading == The City of Albany, State of Oregon. Portland, OR: Lewis & Dryden Printing Co., 1891. "Mayors of Albany: Men Who Have Served Since the Earliest Municipal Organization," Morning Daily Herald [Albany], vol. 4, no. 33 (Jan. 6, 1889), pg. 3.
== Symptoms == Cats will generally show a gradual onset of the disease over a few weeks or months, and it may escape notice for even longer. The first outward symptoms are sudden weight loss (or occasionally gain) accompanied by polydipsia and polyuria. Polyphagia or anorexia may be observed. Neuropathy in the hind legs may cause the cat to develop a plantigrade stance, walking on its hocks rather than its toes. The front legs may develop a corresponding palmigrade stance, with the cat standing on its "palms" rather than its toes. A fasting glucose blood test will normally be suggestive of diabetes at this point. The same home blood test monitors used in humans are also used on cats, usually by obtaining blood from the ear edges or paw pads. As the disease progresses, ketone bodies will be present in the urine, which can be detected with the same urine strips used for testing human urine. In the final stages, the cat starts wasting, with the body breaking down its own fat and muscle to survive. Lethargy/limpness and acetone-smelling breath are acute symptoms of ketoacidosis and/or dehydration and constitute a medical emergency. Untreated, diabetes leads to coma and then death.
The Australian Football League (AFL) started in 1897 and was originally called the Victorian Football League until its name change in 1990 due to its expansion to other Australian states. AFL is often viewed as an iconic Australian sport which attracts large crowds averaging 35,000 people per game. Drugs are usually known as a chemical compound that has an effect on a person's body in some way, either physically or psychologically. Drugs specific to elite sports, such as AFL, can include anabolic steroids and stimulants due to their performance-enhancing effects. The consumption of these drugs is known as doping. Doping is the administration of drugs to enhance the performance of a person or athlete. This can create unfair advantages in the game and also could lead to many health risks to the players that are doping. The AFL also has practices in place related to the use of illicit recreational drugs.
Minoxidil was discovered in 1963 and was introduced for treatment of high blood pressure in 1971. In 1971, researchers unexpectedly discovered that minoxidil causes hair growth, resulting in it being repurposed for treatment of hair loss and approved in topical form for this use in 1988. Topical minoxidil became available over-the-counter in 1996. Low-dose oral minoxidil (LDOM) emerged for treatment of hair loss in 2015 and dramatically increased in popularity starting in 2022. Extended-release oral minoxidil and sublingual minoxidil were developed in the 2020s for hair loss and are in late-stage trials. Aside from its use in humans, minoxidil is extremely toxic to cats and dogs even in small amounts.
Sources: en.wikipedia.org
Lyophilized material is normally held at about minus twenty degrees Celsius in a sealed, desiccated vial. Dissolved samples are less durable and are prepared fresh. Repeated freeze-thaw cycles are avoided.
Mass spectrometry provides the mass of the intact complex and any fragments. Reversed-phase chromatography supplies a purity figure. Visible spectroscopy shows the broad copper absorption band.
Yes, a peptide assay does not reveal the metal-to-peptide ratio. Elemental analysis such as inductively coupled plasma emission quantifies the copper. The value is checked against the expected one-to-one proportion.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide coordinates the metal through its histidine imidazole, terminal amino group, and amide nitrogen. It is studied in biochemistry and dermatological research.